PharmaJet® Enters into MOU Agreement with Egyptian UPA and EVA Pharma to provide Needle-Free Delivery for Routine Immunization in Egypt>

(BUSINESS WIRE)--PharmaJet®, a company that strives to improve the performance and outcomes of injectables with its enabling needle-free injection technology, today announced that it has signed a Memorandum of Understanding (MOU) agreement with the Egyptian Unified Procurement Authority (UPA) and EVA Pharma, one of the leading pharmaceutical companies driving healthcare innovation and access across the Middle East and Africa, to explore the integration of needle-free delivery of inactivated polio vaccine into Egypt’s routine immunization program. The signing event took place in Cairo at the African Health ExCon healthcare conference on June 26. The agreement includes provisions for distribution, technology transfer, manufacturing, and new pharmaceutical product development, as well as collaborating to increase needle-free access within Egypt and regionally. The UPA seeks to incorporate new technologies into its portfolio, aiming to expand the benefits of vaccination against certain infectious agents, improve pandemic preparedness, reduce total immunization costs, and improve foreign exchange rates. Tropis® Needle-free adoption offers several strategic adv...(BUSINESS WIRE)--PharmaJet®, a company that strives to improve the performance and outcomes of injectables with its enabling needle-free injection technology, today announced that it has signed a Memorandum of Understanding (MOU) agreement with the Egyptian Unified Procurement Authority (UPA) and EVA Pharma, one of the leading pharmaceutical companies driving healthcare innovation and access across the Middle East and Africa, to explore the integration of needle-free delivery of inactivated polio vaccine into Egypt’s routine immunization program. The signing event took place in Cairo at the African Health ExCon healthcare conference on June 26. The agreement includes provisions for distribution, technology transfer, manufacturing, and new pharmaceutical product development, as well as collaborating to increase needle-free access within Egypt and regionally. The UPA seeks to incorporate new technologies into its portfolio, aiming to expand the benefits of vaccination against certain infectious agents, improve pandemic preparedness, reduce total immunization costs, and improve foreign exchange rates. Tropis® Needle-free adoption offers several strategic adv...{}